New Key Statistics Module, Z-Score and F-Score
NAS:CARA Key Ratios
| Market Cap $ M | 16.68 |
| Enterprise Value $ M | -21.94 |
| P/E(ttm) | -- |
| PE Ratio without NRI | -- |
| Forward PE Ratio | -- |
| Price/Book | 23.38 |
| Price/Sales | 1.91 |
| Price/Free Cash Flow | -- |
| Price/Owner Earnings | -- |
| Payout Ratio % | -- |
| Revenue (TTM) $ M | 8.00 |
| EPS (TTM) $ | -1.75 |
| Beneish M-Score | -5.25 |
| 10-y EBITDA Growth Rate % | -- |
| 5-y EBITDA Growth Rate % | -- |
| y-y EBITDA Growth Rate % | -- |
| EV-to-EBIT | 0.25 |
| EV-to-EBITDA | 0.25 |
| PEG | -- |
| Shares Outstanding M | 54.86 |
| Net Margin (%) | -1,099.76 |
| Operating Margin % | -919.62 |
| Pre-tax Margin (%) | -1,099.76 |
| Quick Ratio | 4.71 |
| Current Ratio | 4.77 |
| ROA % (ttm) | -104.95 |
| ROE % (ttm) | -258.41 |
| ROIC % (ttm) | -605.23 |
| Dividend Yield % | -- |
| Altman Z-Score | -24.87 |
CARA Number of Guru Trades
CARA Volume of Guru Trades
Gurus Latest Trades with NAS:CARA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
NAS:CARA is held by these investors
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Cara Therapeutics Inc Insider Transactions
No Available Data
News about NAS:CARA
Total 0- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers